EUCTR2013-004385-34-FR进行中（未招募）1 期
Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial - BREGO
Institut régional du Cancer - Montpellier - Val d'Aurelle0 个研究点目标入组 87 人开始时间: 2015年8月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adenocarcinoma of the biliary tract (gallbladder, intra and/or extrahepatic bile ducts, or ampulla of Vater):
- •Cytologically or histologically proven adenocarcinoma of the biliary tract. In case of uncertain biliary tract origin (e.g., intrahepatic, peripheral cholangiocarcinomas), inclusion is possible if i) extensive search for primary origin (thoracic and abdominopelvic Computed Tomography scanner (CT scan), upper digestive endoscopy) is negative; and ii) histological examination is consistent with bile duct adenocarcinoma (ImmunoHistoChemistry (IHC) should ideally be performed and be consistent with biliary primary disease, e.g., positive for cytokeratin 7 and negative for cytokeratin 20).
- •2. Metastatic disease with no curative surgery option or metastatic recurrence after resection.
- •3. At least one measurable lesion in a non-irradiated area according to Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1).
- •4. No biliary obstruction.
- •5. Age between 18 and 75 years.
- •6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •7. Life expectancy higher than 3 months.
- •8. No prior chemotherapy for advanced disease. Previous adjuvant chemotherapy including Gemcitabine and/or platinum based is allowed if completed at least 6 months previously and relapsing after completion of the last dose.
- •9. Total bilirubin = 2.5 times the upper limit of the normal range (ULN). Patients with jaundice or evidence of bile duct obstruction, in whom the biliary tree can be decompressed by endoscopic or percutaneous endoprothesis (at least 15 days before inclusion) with subsequent reduction in total bilirubin = 3 ULN, will be eligible for the study.
- •10. Aminotransferases (AST, ALT) = 2.5 ULN (= 5 ULN in case of diffuse hepatic involvement), INR < 1.5 (following vitamin K1 injection in patients with current or recent history of jaundice or bile duct obstruction), Glomerular Filtration Rate (GFR) > 50 mL/min/1.73m² according to the Modification of Diet in Renal Disease (MDRD) formula, neutrophils = 1.5.10^9/L, platelets = 100.10^9/L, hemoglobin = 9 g/dL (red blood cell transfusion is allowed if needed).
- •11.Signed informed consent obtained before any study specific procedures.
- •12.Patients must be affiliated to a Social Security System.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 44
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 43
排除标准
- •1. Known central nervous system metastases.
- •2. Known history of human immunodeficiency virus (HIV) infection
- •3. Contraindication or history of allergic reaction to one of the treatment components.
- •4. Previous irradiation (external radiotherapy or brachytherapy) within 30 days prior to study treatment.
- •5. Major surgery within 30 days prior to study treatment.
- •6. Participation in another clinical trial within 30 days prior to study treatment.
- •7. Concomitant systemic immunotherapy, chemotherapy, antitumor hormone therapy, targeted therapy or any experimental therapy.
- •8. Active uncontrolled infection, peripheral neuropathy grade = 2, acute or subacute bowel obstruction, history of inflammatory bowel disease, interstitial pneumonitis, respiratory failure, renal failure, dysphagia or any malabsorption condition.
- •9. Symptomatic coronary heart disease or myocardial infarction in the past 6 months, congestive heart failure (NYHA class II), prior cerebrovascular accident.
- •10.Uncontrolled hypertension (systolic blood pressure (BP) > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management).
- •11.Proteinuria of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) = grade 2 (i.e. urinary protein = 1.0 g/24 hrs).
- •12.Patients with current or anticipated need for strong Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers.
- •13.Pregnancy (or positive ß-HCG dosage at inclusion), breast-feeding, or lack of effective contraception in male or female patients of reproductive potential.
- •14.Other malignancies either currently active or in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma.
- •15.Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study.
研究者
相似试验
招募中
1 期
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib for the treatment of chemo-resistant metastatic colorectal cancersMetastatic colorectal cancerMedDRA version: 21.0Level: PTClassification code: 10052358Term: Colorectal cancer metastatic Class: 100000004864CTIS2023-509761-21-00Centre Hospitalier Regional Universitaire174
已完成
1 期
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract CancerDigestive CancerNCT02386397Institut du Cancer de Montpellier - Val d'Aurelle66
进行中（未招募）
1 期
Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer carcinomaAn open-label phase IIMetastatic colorectal cancerEUCTR2020-002344-23-FRCHU de Besançon49
招募中
1 期
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma - REGO-INTER-EWING1ewly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcomaCTIS2023-503322-39-00Institut Gustave Roussy29
已完成
2 期
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint InhibitorsHepatocellular CarcinomaJPRN-jRCT2031200435Tanigawa Takahiko119